SCHEMBL3784898

SCHEMBL3784898

CCOC(=O)c1cccc2c1nc(Cl)c1cccn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
ALDH1A1 P00352 4/20 0.48
GAA P10253 3/20 0.48
GLA P06280 2/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
CYP1A2 P05177 3/20 0.43
MAPK1 P28482 1/20 0.43
CDC25B P30305 1/20 0.42
HSD17B10 Q99714 1/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3784214 0.85 LCK (0.54) KDM4ENPSR1RXFP1ALDH1A1GAA
SCHEMBL3792862 0.84 KDM4E (0.42) KDM4ENPSR1RXFP1ALDH1A1GAA
SCHEMBL5773371 0.82 MAPK1 (0.59) KDM4ENPSR1RXFP1ALDH1A1GAA
SCHEMBL3792096 0.79 ALDH1A1 (0.42) KDM4EALDH1A1HPGDTSHRSMN1; SMN2
SCHEMBL1310923 0.79 KDM4E (0.47) KDM4ENPSR1RXFP1ALDH1A1GAA
SCHEMBL3784901 0.77 SMN1; SMN2 (0.45) KDM4ENPSR1ALDH1A1GAAGLA
SCHEMBL3790281 0.77 ALDH1A1 (0.51) KDM4ENPSR1ALDH1A1HPGDTSHR
SCHEMBL7477457 0.76 TSHR (0.51) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL3790215 0.76 PIM1 (0.50) KDM4ENPSR1ALDH1A1GAAGLA
SCHEMBL9090657 0.75 SMN1; SMN2 (0.59) KDM4EALDH1A1GAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS PIM2, PIM1, PIM3 KDM4E 1746/4885NPSR1 3917/4885RXFP1 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.